JMP reiterates Human Genome at outperform

JMP Securities analyst Charles C. Duncan reiterated Human Genome Sciences, Inc. at a market outperform rating and a $15 price target on new of the company's third-quarter results. Human Genome demonstrated strengthened cash and that two large market potential phase 3 programs are on track to begin in 2006. Human Genome's reported third-quarter financial results included total revenues of $6.7 million and a net loss of $0.46 per share. Shares of the Rockville, Md.-based biopharmaceutical company were down 60 cents, or 4.72%, at $12.11. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.